Loss of peak vision in retinal vein occlusion patients treated for macular edema

The authors are commenting on the article entitled “Loss of peak vision in retinal vein occlusion patiets treated for macular edema” published by Iftikhar et al. in Am J Ophthalmol 2019; 205(September):17-26. After thorough analysis of the issues related to the central retinal vein occlusions, the authors concluded that the central/hemicentral retinal vein occlusion has to be considered an ophthalmic emergency. Therefore, therapy with anti-vascular endothelial growth factor agents has to be promptly applied as soon as possible after central retinal vein occlusion onset. Regardless of the antiangiogenic agents chosen, the treatment paradigms used (e.g., treat-and-extend, pro re nata, fixed-interval, or escalated algorithm), the patient age, the baseline best-corrected visual acuity, and the type of occlusion (ischemic/nonischemic form), the efficacy of treatment depends primarily on the promptness of the therapy after central/hemicentral retinal vein occlusion onset, which can be considered a key driver predicting visual and functional future outcomes.